VPH Stock Overview
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Valeo Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.15 |
52 Week High | CA$0.53 |
52 Week Low | CA$0.13 |
Beta | 2.53 |
1 Month Change | -16.67% |
3 Month Change | -58.33% |
1 Year Change | -67.03% |
3 Year Change | -85.98% |
5 Year Change | -80.77% |
Change since IPO | -76.92% |
Recent News & Updates
Recent updates
Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing
Mar 02Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump
Jan 17Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%
Jun 08Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%
Jun 24Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts
Jun 17Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?
Feb 08Announcing: Valeo Pharma (CSE:VPH) Stock Increased An Energizing 208% In The Last Year
Dec 17Shareholder Returns
VPH | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -6.3% | -9.9% | -3.0% |
1Y | -67.0% | 46.0% | 3.2% |
Return vs Industry: VPH underperformed the Canadian Pharmaceuticals industry which returned 46% over the past year.
Return vs Market: VPH underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
VPH volatility | |
---|---|
VPH Average Weekly Movement | 19.7% |
Pharmaceuticals Industry Average Movement | 14.1% |
Market Average Movement | 9.1% |
10% most volatile stocks in CA Market | 18.3% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: VPH's share price has been volatile over the past 3 months.
Volatility Over Time: VPH's weekly volatility has increased from 15% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 100 | Steve Saviuk | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
VPH fundamental statistics | |
---|---|
Market cap | CA$14.80m |
Earnings (TTM) | -CA$28.43m |
Revenue (TTM) | CA$54.29m |
0.3x
P/S Ratio-0.5x
P/E RatioIs VPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VPH income statement (TTM) | |
---|---|
Revenue | CA$54.29m |
Cost of Revenue | CA$40.84m |
Gross Profit | CA$13.44m |
Other Expenses | CA$41.88m |
Earnings | -CA$28.43m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.29 |
Gross Margin | 24.76% |
Net Profit Margin | -52.37% |
Debt/Equity Ratio | -138.2% |
How did VPH perform over the long term?
See historical performance and comparison